SARS

Novel monoclonal antibodies neutralize SARS coronavirus in vitro

Published in Immunotherapy Weekly, April 6th, 2005

Novel monoclonal antibodies (mAbs) targeting key SARS coronavirus (SARS-CoV) proteins have been shown to neutralize the virus in vitro.

The availability of SARS-CoV-specific mAbs "is important for the development of both diagnostic tools and treatment of infection," immunologists in Canada explained.

In their study, M.J. Gubbins and coauthors at the National Microbiology Laboratory in Winnipeg evaluated "nine monoclonal antibodies raised in immune mice, using highly purified, inactivated SARS-CoV as the inoculating antigen."

"These antibodies are specific for numerous viral protein targets, and six of them are able to effectively...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Immunotherapy Weekly

Source: Immunotherapy Weekly (2005-04-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry